Chinese Academy of Sciences Jun 6 2025 Non-small cell lung cancer (NSCLC) accounts for the majority of lung cancer cases and remains a leading cause of cancer mortality worldwide. Epidermal growth factor receptor (EGFR) mutations are common in NSCLC and have made EGFR-targeting drugs like osimertinib a cornerstone of treatment. Immune checkpoint inhibitors have also transformed the treatment landscape by reactivating the immune system to attack tumors. Despite their promise, combining these two